etodolac has been researched along with Cancer of Stomach in 4 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among 267 early gastric cancer patients who underwent endoscopic resection, 47 patients with extensive metaplastic gastritis were selected based on endoscopic findings and our previously described criteria of serum pepsinogen (PG) test-positive and Helicobacter pylori antibody-negative conditions." | 6.75 | Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. ( Deguchi, H; Enomoto, S; Fujishiro, M; Ichinose, M; Iguchi, M; Inada, K; Inoue, I; Maekita, T; Mukoubayashi, C; Nakamura, Y; Oka, M; Takeshita, T; Tamai, H; Tsukamoto, T; Ueda, K; Utsunomiya, H; Yanaoka, K; Yoshimura, N, 2010) |
| "Among 267 early gastric cancer patients who underwent endoscopic resection, 47 patients with extensive metaplastic gastritis were selected based on endoscopic findings and our previously described criteria of serum pepsinogen (PG) test-positive and Helicobacter pylori antibody-negative conditions." | 2.75 | Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. ( Deguchi, H; Enomoto, S; Fujishiro, M; Ichinose, M; Iguchi, M; Inada, K; Inoue, I; Maekita, T; Mukoubayashi, C; Nakamura, Y; Oka, M; Takeshita, T; Tamai, H; Tsukamoto, T; Ueda, K; Utsunomiya, H; Yanaoka, K; Yoshimura, N, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sano, T | 1 |
| Ozaki, K | 1 |
| Kodama, Y | 1 |
| Matsuura, T | 1 |
| Narama, I | 1 |
| Yanaoka, K | 2 |
| Oka, M | 3 |
| Yoshimura, N | 1 |
| Deguchi, H | 1 |
| Mukoubayashi, C | 1 |
| Enomoto, S | 2 |
| Maekita, T | 1 |
| Inoue, I | 1 |
| Ueda, K | 1 |
| Utsunomiya, H | 2 |
| Iguchi, M | 1 |
| Tamai, H | 2 |
| Fujishiro, M | 1 |
| Nakamura, Y | 1 |
| Tsukamoto, T | 2 |
| Inada, K | 2 |
| Takeshita, T | 1 |
| Ichinose, M | 2 |
| Magari, H | 1 |
| Shimizu, Y | 1 |
| Tomeki, T | 1 |
| Arii, K | 1 |
| Nakata, H | 1 |
| Tsutsumi, Y | 1 |
| Tatematsu, M | 1 |
| Iwata, C | 1 |
| Kano, MR | 1 |
| Komuro, A | 1 |
| Kiyono, K | 1 |
| Johansson, E | 1 |
| Morishita, Y | 1 |
| Yashiro, M | 1 |
| Hirakawa, K | 1 |
| Kaminishi, M | 1 |
| Miyazono, K | 1 |
1 trial available for etodolac and Cancer of Stomach
| Article | Year |
|---|---|
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion.
Topics: Aged; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Follow-Up Studies; Gastritis; Helicobacter pylo | 2010 |
3 other studies available for etodolac and Cancer of Stomach
| Article | Year |
|---|---|
Paradoxical effects of a selective cyclooxygenase-2 inhibitor, etodolac, on proliferative changes of forestomach in alloxan-induced diabetic rats.
Topics: Alloxan; Animals; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Diabetes Mellitus, Experimental; | 2009 |
Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils.
Topics: Animals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Etodolac; Gerbillinae; Helicob | 2005 |
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etodolac; Humans; Inflammation; Lymphangioge | 2007 |